Search
Ensifentrine
go.drugbank.com/drugs/DB16157ApprovedInvestigational[L50903] On June 26, 2024, the FDA announced the approval of an inhaled product of ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD) in adults, which allows the drug to be … [L50903] It works to induce bronchodilator and reduce inflammation in COPD.[A263913]
Synonyms: N-(2-((2E)-9,10-DIMETOXI-4-OXO-2-((2,4,6-TRIMETILFENIL)IMINO)-6,7-DIHIDRO-2H-PIRIMIDO(6,1-A)ISOQUINOLEIN-3(4H)-IL)ETIL)UREA, UREA, N-(2-(6,7-DIHYDRO-9,10-DIMETHOXY-4-OXO-2-((2,4,6-TRIMETHYLPHENYL)IMINO)-2H-PYRIMIDO(6,1-A)ISOQUINOLIN-3(4H)-YL)ETHYL)-Imdevimab
go.drugbank.com/drugs/DB15940ApprovedInvestigational[A221495] On November 21, 2020, the FDA authorized emergency approval of REGN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. … [L23524] In November 2021, the same indication was approved by the EMA.
Ferric sulfate
go.drugbank.com/drugs/DB11171ApprovedIt is produced by the reaction of sulfuric acid and an oxidizing agent. … [A32355, A32356] By the FDA, ferric sulfate is a direct food substance affirmed in the GRAS category (Generally Recognized As Safe).[L2003]
Remibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigationalThe FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators.
Lasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigationalLasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019. … [sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety.
Sirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigational[A242417] Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. … [A1320] Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants.
Products: LIKMUN-ELusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalan invasive medical procedure [A36730]. … In September 2015, lusutrombopag received its first global approval in Japan to reduce the need for platelet transfusion in adults with chronic liver disease and thrombocytopenia who are schedule to undergo
Formaldehyde
go.drugbank.com/drugs/DB03843ApprovedVet approved(From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p717) … In solution, it has a wide range of uses: in the manufacture of resins and textiles, as a disinfectant, and as a laboratory fixative or preservative.
Categories: Compounds used in a research, industrial, or household settingPyrantel
go.drugbank.com/drugs/DB11156ApprovedVet approvedPyrantel is on the World Health Organization's List of Essential Medicines, which are the safest and most effective medicines required in a functioning health system [L1901], [L1902]. … Pyrantel was initially described in 1965 by researchers from Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of action) for use as an anthelmintic drug
Tofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalTofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. … It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.